A $1.5 billion acquisition will expand cell therapy capabilities and recurring revenue, with BioLife stockholders receiving a 24% premium. The deal is expected to be accretive, deliver significant synergies, and close in Q4 2026, pending regulatory and stockholder approvals.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.